|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004147,
umls-concept:C0008976,
umls-concept:C0012373,
umls-concept:C0016018,
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0175668,
umls-concept:C0199176,
umls-concept:C0542269,
umls-concept:C0681698,
umls-concept:C0687676,
umls-concept:C0719166,
umls-concept:C1274040,
umls-concept:C1414461
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1997-7-7
|
|
pubmed:abstractText |
To describe the rationale and design of the Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial (PROTECT).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0828-282X
|
|
pubmed:author |
pubmed-author:BasuDD,
pubmed-author:DoraG LGL,
pubmed-author:GoodmanSS,
pubmed-author:HigginsonLL,
pubmed-author:HillCC,
pubmed-author:LamJJ,
pubmed-author:LangerAA,
pubmed-author:MasseiGG,
pubmed-author:McCannGG,
pubmed-author:NasmithJJ,
pubmed-author:StantonEE,
pubmed-author:ThompsonCC,
pubmed-author:WarnicaWW
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1183-90
|
|
pubmed:dateRevised |
2008-4-9
|
|
pubmed:meshHeading |
pubmed-meshheading:9191511-Adrenergic beta-Antagonists,
pubmed-meshheading:9191511-Adult,
pubmed-meshheading:9191511-Atenolol,
pubmed-meshheading:9191511-Calcium Channel Blockers,
pubmed-meshheading:9191511-Death, Sudden, Cardiac,
pubmed-meshheading:9191511-Diltiazem,
pubmed-meshheading:9191511-Double-Blind Method,
pubmed-meshheading:9191511-Electrocardiography,
pubmed-meshheading:9191511-Female,
pubmed-meshheading:9191511-Follow-Up Studies,
pubmed-meshheading:9191511-Humans,
pubmed-meshheading:9191511-Male,
pubmed-meshheading:9191511-Myocardial Infarction,
pubmed-meshheading:9191511-Recurrence
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
|
|
pubmed:affiliation |
St Michael's Hospital Clinical Trials Unit, University of Toronto, Ontario. goodmans@smh.toronto.on.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
